ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Abbott Pulls Trifecta Heart Valves off the Market Due to Early Deterioration
Submitted by
Source
Because of the potential risk of early structural valve deterioration, the FDA has sent notice about Abbott’s decision to stop selling and distributing Trifecta aortic surgical heart valves in the United States. The FDA recommends that healthcare providers be aware of the risk of SVD with Trifecta valves, discuss risk with patients, and monitor patients who have undergone implantation with Trifecta valves.Because of the potential risk of early structural valve deterioration, the FDA has sent notice about Abbott’s decision to stop selling and distributing Trifecta aortic surgical heart valves in the United States. The FDA recommends that healthcare providers be aware of the risk of SVD with Trifecta valves, discuss risk with patients, and monitor patients who have undergone implantation with Trifecta valves.
Printer-friendly
